Skip to main content
Signal8

Jaguar Health, Inc. (JAGX) Form 424B5 — Nov 9, 2026

$JAGXForm 424B5Filed Nov 9, 2026, 8:37 AM ET0001193125-26-452741Original filing

Jaguar Health filed a 424B5 prospectus supplement for a new $75 million at-the-market offering of common stock through Ladenburg Thalmann, on top of roughly $104 million already sold under prior ATM registrations. The offering is priced off a $0.4988 closing price, and a full draw would grow shares outstanding from about 13.3 million to about 163.7 million — more than 12x the current share count. The filing comes shortly after a 1-for-15 reverse stock split (September 2026) and a string of dilutive preferred/note exchanges with Streeterville and Lincoln Alternative Strategies, underscoring that this capital raise is a survival necessity rather than opportunistic.

Key figures

Gross Proceeds
75000000
Offering Price
0.4988
Shares Outstanding
13,345,986 prior; 163,706,852 after full sale at $0.4988
Commission
3% of gross sales price
Reverse split ratio
1-for-15 (effective September 17, 2026)
Dilution to new investors
$0.03 per share
Estimated offering expenses
$385,000 plus $75,000 counsel reimbursement
Series p redemption obligation
10% of ATM net proceeds must redeem Series P Preferred Stock
Net tangible book value june 2026
$(10.2) million or $(31.39) per share
Prior atm sales 2021 registration
$71.8 million
Prior atm sales 2024 registration
$32.1 million

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.